Urology Practice Management - March 2020, Vol 6, No 1
Combining cabozantinib (Cabometyx) with atezolizumab (Tecentriq) induced responses in 32% of patients with metastatic castration-resistant prostate cancer (CRPC) who had soft-tissue progression after previous novel hormonal therapy.
Telemedicine will play a significant role in contemporary urologic practices. Although only a small percentage of urologists currently use this technology, many more practices are going to embrace it in the near future.1
The American Society of Clinical Oncology (ASCO) recently released a major update to its Patient-Centered Oncology Payment (PCOP) model, an alternative payment model designed to enable all oncology practices to deliver higher-quality care at lower cost.
De-escalating chemotherapy based on a negative positron emission tomography (PET) scan after 2 cycles of treatment is safe and feasible in most patients with low-volume metastatic seminoma, the most common type of testicular cancer, according to results presented at the 2020 Genitourinary Cancers Symposium.
MicroRNAs have all the characteristics to be a potential game changer as a biomarker in germ-cell tumors (originating in the testes, ovaries, and a few other sites), with high sensitivity, specificity, and clinical validity in pilot studies, said Lucia Nappi, MD, PhD, Medical Oncologist, British Columbia Cancer, Vancouver Centre, Canada, at the 2020 Genitourinary Cancers Symposium.
The Ohio-based company, PercuVision, LLC, developer of the telemedicine platform DirectVision DVS-III Telehealth Hub, and LocumTenens.com, a full-service healthcare staffing agency aligned with Georgia’s Jackson Healthcare network, have joined forces to launch a pilot program that will provide valuable clinical and emergency tele-urology services to patients across the United States.
The clinical course of prostate cancer is highly variable, reflecting the heterogeneity of the disease. Although most men diagnosed with prostate cancer have low-risk, favorable disease characteristics, some may harbor aggressive features and experience disease progression despite conventional therapy.
The discontinuation of oral oncology medications before the full-month supply has been finished results in medication waste, leading to increased costs for patients and for payers. Split fills allow for a 14- to 16-day supply for oral oncology medications rather than a full 28- to 30-day supply.
Results 1 - 8 of 8